NCT07462065 Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate
| NCT ID | NCT07462065 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | PAEC General Hospital, Islamabad |
| Condition | Infertility Treatment |
| Study Type | INTERVENTIONAL |
| Enrollment | 62 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 62 participants in total. It began in 2026-03-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Women who meet the study requirements will be enrolled and randomly assigned by a computer system to receive either pioglitazone 30 mg daily or a placebo starting from the second day of their menstrual period for the same duration. All participants will also take clomiphene citrate 150 mg daily from day 3 to day 7 of the menstrual cycle. A transvaginal ultrasound will be performed on day 10 of the menstrual cycle to assess the growth of ovarian follicles, and the number of mature follicles (16-24 mm) will be recorded. If at least one mature follicle measuring 16-24 mm is present and the endometrial thickness is at least 7 mm, an injection of human chorionic gonadotropin (hCG) will be given to trigger ovulation, followed by an intrauterine insemination (IUI) procedure. Participants will be followed until the end of the menstrual cycle, and if the menstrual period is delayed by 5 days, a blood test for β-hCG will be performed to confirm pregnancy. Any side effects during the treatment period, such as swelling, fluid retention, blurred vision, or weight gain, will be recorded.
Eligibility Criteria
Inclusion Criteria: Normal hysterosalpingography Normal spermogram Suffering from PCOS Ovarian cysts less than 20mm. Exclusion Criteria: History of chronic cardiovascular disease Chronic kidney disease Diabetes Thyroid disease Pulmonary disease
Contact & Investigator
Musarat Ashraf, MBBS,FCPS
STUDY CHAIR
Head of Department
Frequently Asked Questions
Who can join the NCT07462065 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 38 Years, studying Infertility Treatment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07462065 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07462065 currently recruiting?
Yes, NCT07462065 is actively recruiting participants. Contact the research team at kinza.azharr@gmail.com for enrollment information.
Where is the NCT07462065 trial being conducted?
This trial is being conducted at Islamabad, Pakistan.
Who is sponsoring the NCT07462065 clinical trial?
NCT07462065 is sponsored by PAEC General Hospital, Islamabad. The principal investigator is Musarat Ashraf, MBBS,FCPS at Head of Department. The trial plans to enroll 62 participants.